300 related articles for article (PubMed ID: 9743156)
1. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
Bénard F; Sterman D; Smith RJ; Kaiser LR; Albelda SM; Alavi A
Chest; 1998 Sep; 114(3):713-22. PubMed ID: 9743156
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
3. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
[TBL] [Abstract][Full Text] [Related]
4. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
5. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
6. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
7. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
Gerbaudo VH; Sugarbaker DJ; Britz-Cunningham S; Di Carli MF; Mauceri C; Treves ST
J Nucl Med; 2002 Sep; 43(9):1144-9. PubMed ID: 12215551
[TBL] [Abstract][Full Text] [Related]
8. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
Pilling J; Dartnell JA; Lang-Lazdunski L
Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
Schneider DB; Clary-Macy C; Challa S; Sasse KC; Merrick SH; Hawkins R; Caputo G; Jablons D
J Thorac Cardiovasc Surg; 2000 Jul; 120(1):128-33. PubMed ID: 10884665
[TBL] [Abstract][Full Text] [Related]
10. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
Carretta A; Landoni C; Melloni G; Ceresoli GL; Compierchio A; Fazio F; Zannini P
Eur J Cardiothorac Surg; 2000 Apr; 17(4):377-83. PubMed ID: 10773558
[TBL] [Abstract][Full Text] [Related]
11. Is FDG-PET/CT useful for managing malignant pleural mesothelioma?
Otsuka H; Terazawa K; Morita N; Otomi Y; Yamashita K; Nishitani H
J Med Invest; 2009 Feb; 56(1-2):16-20. PubMed ID: 19262009
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).
Niccoli-Asabella A; Notaristefano A; Rubini D; Altini C; Ferrari C; Merenda N; Fanelli M; Rubini G
Clin Imaging; 2013; 37(6):1098-103. PubMed ID: 23932389
[TBL] [Abstract][Full Text] [Related]
13. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
Basu S; Saboury B; Torigian DA; Alavi A
Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
[TBL] [Abstract][Full Text] [Related]
14. [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].
Meignan M; Paone G
Rev Pneumol Clin; 2006 Apr; 62(2):128-34. PubMed ID: 16670667
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
Flores RM; Akhurst T; Gonen M; Larson SM; Rusch VW
J Thorac Cardiovasc Surg; 2003 Jul; 126(1):11-6. PubMed ID: 12878934
[TBL] [Abstract][Full Text] [Related]
16. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
Tan C; Barrington S; Rankin S; Landau D; Pilling J; Spicer J; Cane P; Lang-Lazdunski L
J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
[TBL] [Abstract][Full Text] [Related]
17. 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.
Roca E; Laroumagne S; Vandemoortele T; Berdah S; Dutau H; Maldonado F; Astoul P
Lung Cancer; 2013 Feb; 79(2):187-90. PubMed ID: 23206832
[TBL] [Abstract][Full Text] [Related]
18. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
Kitajima K; Doi H; Kuribayashi K
Jpn J Radiol; 2016 Aug; 34(8):537-47. PubMed ID: 27222020
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
20. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
